Multiple myeloma: So much progress, but so many unsolved questions

Haematologica

Volumn 98, Issue 4, 2013, Pages 487-489

  Moreau, Philippe ^a,b   Minvielle, Stéphane ^b  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER CHEMOTHERAPY; DRUG MEGADOSE; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; RELAPSE; REMISSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; OUTCOME ASSESSMENT (HEALTH CARE); PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84875654640     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.083592     Document Type: Editorial

References (23)

1. Moreau P, Avet-Loiseau H, Harousseau JL, Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011;29(14):1898-906.
2. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063-73.
3. San-Miguel JF, Mateos MV. Can multiple myeloma become a curable disease? Haematologica. 2011;96(9):1246-8.
4. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
5. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679-86.
6. Boccadoro M, Cavallo F, Nagler A, Ben Yehuda D, Omedè P, Cavalli M, et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: a phase III trial. J Clin Oncol. 2011;29(15 Suppl):(Abstract 8020).
7. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335-48.
8. Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115(21);4168-73.
9. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proceed. 2009;84(12):1095-110.
10. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011(18);117:4691-5.
11. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12):2077-84.
12. Terragna C, Zamagni E, Petrucci MT, Durante S, Patriarca F, Narni F, et al. Molecular remission after bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone as consolidation therapy following double autologous transplantation for multiple myeloma: results of a qualitative and quantitative analysis. Blood. 2010;116 (21):861.
13. Paiva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood. 2009;114(20):4369-72.
14. Pawlyn C, Davies FE, Gregory WM, Szubert AJ, Bell SE, Ouzman J, et al. Sequential immunomodulatory drug and proteasome inhibitor therapy improves response rates in newly diagnosed multiple myeloma: preliminary results from the Myeloma XI trial. Blood. 2010;120:Abstract 335.
15. Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2008;26(29):4798-805.
16. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543-53.
17. Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res. 2010;16(6):1856-64.
18. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET-CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989-95.
19. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120(5):1060-6.
20. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067-76.
21. Magrangeas F, Avet-Loiseau H, Gouraud W, Lodé L, Decaux O, Godmer P, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia. 2013;27(2):473-81.
22. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012;120(5):1077-86.
23. Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood. 2011;118(3):675-8.